The global multiple myeloma market size is projected to reach USD 31 billion by the end of 2026. The high prevalence of the disease will emerge in favor of the companies operating in the market. According to a report published by Fortune Business Insights, titled “Multiple Myeloma Market Size, Share & Industry Analysis, By Drug Class (Immunomodulators, Proteasome Inhibitor, Anti-CD38 Monoclonal Antibody, Alkylating Agents, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies), and Regional Forecast, 2019-2026,”
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/multiple-myeloma-market-102693
Detailed Table of Content:
- Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
- Executive Summary
- Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
- Key Insights
4.1. Prevalence of Multiple Myeloma - by Key Countries - 2018
4.2. Pipeline Analysis
4.3. Key Industry Developments
4.4. Regulatory Scenario, by Key Regions
4.5. Analysis Of Economic Burden of Multiple Myeloma Treatment
4.6. New Product Launches
4.7. Overview of Emerging Treatments for Multiple Myeloma
- Global Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Class
5.2.1. Immunomodulators
5.2.2. Proteasome Inhibitor
5.2.3. Anti-CD38 Monoclonal Antibody
5.2.4. Alkylating Agents
5.2.5. Others
5.3. Market Analysis, Insights and Forecast – By Distribution Channel
5.3.1. Hospital Pharmacies
5.3.2. Retail Pharmacies & Drug Stores
5.3.3. Online Pharmacies
5.4. Market Analysis, Insights and Forecast – By Region
5.4.1. North America
5.4.2. Europe
5.4.3. Asia Pacific
5.4.4. Latin America
5.4.5. Middle East & Africa
- North America Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis – By Drug Class
6.2.1. Immunomodulators
6.2.2. Proteasome Inhibitor
6.2.3. Anti-CD38 Monoclonal Antibody
6.2.4. Alkylating Agents
6.2.5. Others
6.3. Market Analysis – By Distribution Channel
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies & Drug Stores
6.3.3. Online Pharmacies
6.4. Market Analysis – By Country
6.4.1. U.S.
6.4.2. Canada
the United States, Eu5(the UK, Germany, France, Italy, Spain), China and Japan, was $16.27bn in 2019 and is increasing with a modest CAGR during the study period (2017-2030), according to DelveInsight, a leading company in healthcare analytics and consulting.
In the case of China, higher usage of thalidomide based regimen found in the first-line settingAmong emerging therapies, Bristol Myers Squibb and Bluebird Bio's anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) is expected to result in significant revenues owing to promising results, one-time dosing and premium pricing in heavily pretreated patientsKey Companies fuelling the Multiple Myeloma market size growth are GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca etc.Patent expiry of multiple blockbuster drugs like Revlimid, Pomalyst, Darzalex and Kyprolis is on the lines to expire from 2026 onwards, and this will erode the sales value significantly and the market is expected to decline from 2028 onwards due to cumulative impacts of patent expiry.Download Multiple Myeloma Sample: https://www.delveinsight.com/sample-request/multiple-myeloma-marketThough Multiple Myeloma is not common cancer; still, it is the second most diagnosed blood cancer in the United States.
It is worth highlighting that it is a heterogeneous haematological malignancy in which epidemiology plays an increasingly important role.
Over the past years, intensive clinical and molecular epidemiological research has extended the information about its pathogenesis, risk factors, and prognostic components which aided the approval of new drugs.
Darzalex is also being used by the healthcare experts in combination as doublet, triplet, and quadruplet with existing therapies for the good treatment strategies and better result outcomes and has impacted the MM treatment landscape significantly.
Report includes exhaustive analysis of Multiple Myeloma Pipeline TherapiesIdecabtagene vicleucel (ide-cel): Bristol Myers Squibb and bluebird bioVenetoclax (Venclexta, Venclyxto): AbbVieJNJ-68284528 LCAR-B38M/JNJ-4528): Janssen Research and DevelopmentKeytruda (pembrolizumab): NovartisMelflufen (melphalan flufenamide): OncopeptidesCetrelimab (JNJ-63723283): Janssen Research and DevelopmentREGN5458: Regeneron PharmaceuticalsIberdomide: CelgeneNY-ESO-1 C259 T Cells: GlaxoSmithKlineBraftovi (encorafenib): PfizerJCARH125: Celgene CorporationFelzartamab (MOR202): I-Mab BiopharmaChidamide (Epidaza): Shenzhen Chipscreen BioscienceThe past couple of decades have shown vast changes in the treatment landscape of Multiple Myeloma, starting with the use of stem cells trailed by the availability of novel treatments such as immunomodulators and proteasome inhibitors that have transformed the natural history of the indication, leading to increased survival times.
